Latest market price
4.25
-0.10-2.30%
News
Down 2.3% — Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Yahoo).
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.11 | Insider Own | — | Shs Outstand | 57.18M | Perf Week | -1.39% |
| Market Cap | 243.03M | Forward P/E | — | EPS next Y | -0.18 | Insider Trans | -0.98% | Shs Float | 36.09M | Perf Month | -15.51% |
| Enterprise Value | 115.03M | PEG | — | EPS next Q | -0.14 | Short Float | 47.70% | Perf Quarter | -37.68% | ||
| Income | -62.00M | P/S | 9.72 | EPS this Y | -184.50% | Short Ratio | 12.20 | Perf Half Y | -28.57% | ||
| Sales | 25.00M | P/B | 1.90 | EPS next Y | — | ROA | -35.03% | Short Interest | 17.21M | Perf YTD | -19.35% |
| Book/sh | 2.24 | P/C | 1.65 | EPS next 5Y | — | ROE | -41.69% | 52W High | 7.65 -44.44% | Perf Year | -16.34% |
| Cash/sh | 2.57 | P/FCF | — | EPS past 3/5Y | — | ROIC | -39.66% | 52W Low | 4.00 6.25% | Perf 3Y | 10.68% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 81.71% -9.71% | Gross Margin | 56.63% | Volatility | 5.04% 4.59% | Perf 5Y | -79.76% |
| Dividend TTM | — | EV/Sales | 4.60 | EPS Y/Y TTM | -281.18% | Oper. Margin | -327.64% | ATR (14) | 0.22 | Perf 10Y | -97.96% |
| Dividend Ex-Date | Mar 31, 2000 | Quick Ratio | 6.40 | Sales Y/Y TTM | — | Profit Margin | -246.42% | RSI (14) | 33.90 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.63 | EPS Q/Q | -120.47% | SMA20 | -7.32% | Beta | 1.45 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.15 | Sales Q/Q | — | SMA50 | -18.37% | Rel Volume | 0.75 | Prev Close | 4.35 |
| Employees | 226 | LT Debt/Eq | 0.05 | Earnings | Nov 11 | SMA200 | -22.55% | Avg Volume | 1.36M | Price | 4.25 |
| IPO Date | Sep 19, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -51.08% -7.01% | Net Debt/EBITDA | — | Volume | 1,011,826 | Change | -2.30% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-26 | Initiated | Roth Capital | Buy | $17 |
| Aug-14-26 | Reiterated | Industrial Alliance Securities | $15 | |
| Aug-14-26 | Reiterated | Oppenheimer | Outperform | $16 |
| Mar-17-26 | Reiterated | Stifel Nicolaus | $17 | |
| May-16-25 | Reiterated | Stifel Nicolaus | ||
| Mar-05-25 | Initiated | Oppenheimer | Outperform | $16 |
| Nov-14-22 | Reiterated | Leerink Partners | $6.00 | |
| Nov-30-21 | Downgrade | SVB Leerink | Outperform → Market Perform | |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
Latest News· Times ET
Nov-02-26
Nov-02-2607:46AM
Oct-23-26
Oct-23-2610:43AM
Oct-16-26
Oct-16-2602:59AM
Oct-06-26
Oct-06-2606:32PM
Oct-02-26
Oct-02-2607:30AM
Oct-01-26
Oct-01-2610:00AM
Sep-29-26
Sep-29-2605:43PM
Sep-22-26
Sep-22-2606:13PM
06:02PM
04:02AM
Sep-18-26
Sep-18-2607:51AM
07:30AM
Sep-17-26
Sep-17-2602:09AM
Sep-16-26
Sep-16-2604:31PM
Company
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 25 | 6 | 0 | 4 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11 | 2 | 3 | 2 | — | — | — | — | — | |
| Gross Profit | 15 | 4 | -3 | 2 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 73 | 65 | 30 | 19 | — | — | — | — | — | |
| Research and Development | 26 | 27 | 34 | 31 | — | — | — | — | — | |
| Other Operating Expense | -1 | 2 | -3 | -1 | — | — | — | — | — | |
| Operating Income | -84 | -89 | -64 | -47 | — | — | — | — | — | |
| Interest Expense | 4 | 4 | 4 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 164 | 5 | -7 | — | — | — | — | — | |
| Net Income Before Taxes | -78 | 71 | -64 | -54 | — | — | — | — | — | |
| Income Taxes | -15 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -62 | 71 | -64 | -54 | — | — | — | — | — | |
| Net Income From Continuing Operations | -62 | 71 | -64 | -54 | — | — | — | — | — | |
| Net Income | -62 | 71 | -64 | -54 | — | — | — | — | — | |
| EPS (Recurring) | -1.14 | 1.34 | -1.55 | -2.53 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.14 | 1.34 | -1.55 | -2.53 | — | — | — | — | — | |
| EPS (Diluted) | -1.11 | 1.01 | -1.55 | -2.53 | — | — | — | — | — | |
| EBITDA | -72 | 79 | -57 | -51 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 5.22 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.69 | 46.55 | — | 26.30 | — | — | — | — | — | |
| Gross Margin | 60.00 | 66.67 | — | 50.00 | — | — | — | — | — | |
| Operating Margin | -336.00 | -1,483.33 | — | -1,175.00 | — | — | — | — | — | |
| Net Margin | -248.00 | 1,183.33 | — | -1,350.00 | — | — | — | — | — | |
| Shares Outstanding | 57 | 53 | 41 | 21 | — | — | — | — | — | |
| Market Capitalization | 242 | 279 | 228 | 105 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer | Sep 29 '26 | Sale | 5.16 | 9,191 | 47,385 | 482,888 | Sep 29 |
| Seshadri Vishwas | Chief Executive Officer | Sep 29 '26 | Sale | 5.16 | 19,608 | 101,091 | 1,286,500 | Sep 29 |
| Vasanthavada Madhav | Chief Commercial Officer | Sep 29 '26 | Sale | 5.16 | 4,902 | 25,273 | 285,721 | Sep 29 |
| O'Malley Brendan M. | SVP, Chief Legal Officer | Sep 29 '26 | Sale | 5.16 | 6,727 | 34,682 | 421,226 | Sep 29 |
| Alvino Mark | Director | Sep 01 '26 | Sale | 5.86 | 15,000 | 87,966 | 62,065 | Sep 01 |
| Vazzano Joseph Walter | Chief Financial Officer | Jul 21 '26 | Sale | 6.53 | 1,478 | 9,651 | 492,079 | Jul 22 |
| Vasanthavada Madhav | Chief Commercial Officer | Jul 09 '26 | Sale | 6.96 | 12,606 | 87,784 | 290,623 | Jul 09 |
| Vazzano Joseph Walter | Chief Financial Officer | Jul 09 '26 | Sale | 6.96 | 24,880 | 173,257 | 493,557 | Jul 09 |
| Seshadri Vishwas | Chief Executive Officer | Jul 09 '26 | Sale | 6.96 | 67,971 | 473,330 | 1,306,108 | Jul 09 |
| O'Malley Brendan M. | SVP, Chief Legal Officer | Jul 09 '26 | Sale | 6.96 | 12,050 | 83,913 | 427,953 | Jul 09 |
| Alland Leila | Director | Jun 30 '26 | Sale | 5.92 | 11,000 | 65,087 | 162,614 | Jul 02 |
| Silverstein Christine Berni | Director | Jun 15 '26 | Sale | 5.71 | 18,160 | 103,695 | 119,562 | Jun 15 |
| Seshadri Vishwas | Chief Executive Officer | Jun 09 '26 | Sale | 5.30 | 31,916 | 169,289 | 1,374,079 | Jun 09 |
| O'Malley Brendan M. | SVP, Chief Legal Officer | Jun 09 '26 | Sale | 5.30 | 6,305 | 33,443 | 440,003 | Jun 09 |
| Vasanthavada Madhav | Chief Commercial Officer | Jun 09 '26 | Sale | 5.30 | 5,450 | 28,908 | 303,451 | Jun 09 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.